Overview
- The Defense Department directed routine annual testosterone testing for service members 30 and older and allowed younger personnel to opt in, with those who test low offered optional testosterone replacement therapy.
- Military leaders framed the move as a readiness measure intended to boost performance and longevity, but the Pentagon has not released diagnostic cutoffs, confirmatory testing rules, monitoring plans, cost estimates, or gender-specific protocols.
- Endocrinologists and medical societies say population screening departs from clinical practice that tests only when persistent symptoms appear and requires repeat morning tests before treating.
- Experts warned of concrete harms from testosterone replacement therapy such as thicker blood that raises clot risk, impaired sperm production and fertility, liver and prostate concerns, and mood changes.
- Commentators tied the policy to wider political and cultural messaging about masculinity, and congressional oversight and internal Pentagon reviews remain ongoing as implementation details are developed.